The Miserly care not about safety: Drug prices questioned

This would most definitely lead to a cut in innovation, even though The Washington Monthly’s reports that that objection can be met by regulation proponents.

This would apply largely, to genetically modified drugs that cost a great deals in testing, to develop and to pass through the regulators. Ironically, this drive for reduction of prices comes at a time when some of the largest selling drugs are about to come off the shelf- all patentless including Prozac and Zocor- frightening Wall Street away from the industry.

While there is a definite divergence of opinion as to whether” this is right move to make?”. However, it must be seen as per several of our previous posts, there is a definite grouse against the leading pharmaceutical companies for maintaining several essential medicines at such high rates. Perhaps this is the right time that the Americans take note of this situation and concentrate their efforts on safety and awareness and better drugs to combat all situations, rather than the rising economy.

Find the full report here.